Table of Contents
Use this report to:
- Analyze the challenges and opportunities of developing generic drugs and compare difference fast track drug development approaches.
- Provide detailed market, technology and industry analyses to help readers quantify and qualify the market for prescription generic drugs.
- Examine strategies employed by companies specializing in generics to meet the challenges of this highly competitive market.
- Discuss the current size and growth of the generics industry, both in global terms and analyzed by the most important national markets.
- The global market for generic drugs should reach $533 billion by 2021 from $352 billion in 2016 at a compound annual growth rate (CAGR) of 8.7%, from 2016 to 2021.
- The BRIC markets region of the generic drugs industry is the largest market. The market is expected to grow from $132 billion in 2016 to $219 billion in 2021 at a CAGR of 10.7% for the period 2016-2021.
- The North America region of the generic drugs industry is expected to grow from $112 billion in 2016 to $180 billion in 2021 at a CAGR of 10.0% for the period 2016-2021.
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for prescription generic drugs. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2018; these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics and other factors that directly affect the generic drug market. The wider economic environment is also taken into account.
REASONS FOR DOING THE STUDY
This is a time of growth and change for the generic pharmaceutical sector. Major aspects that have combined to create an opportunity for an up-to date market analysis include the following:
- The demand for generics is increasing steadily because of pressure to control healthcare costs. At the same time, fierce price competition in this area has put some companies in difficulties because of slashed profit margins. The main result has been a wave of M&A activity, and the rise of “supergenerics” offering added value as well as low prices. Not all traditional companies are positioned to exploit this trend.
- A major growth driver for the generics sector is the fact that several blockbuster pharmaceutical brands are coming off-patent and are therefore open to generic competition – the phenomenon widely known as the “patent cliff.” But the originator companies are deploying formidable strategies to protect their franchise, including marketing their own branded generics.
- With first-generation biopharmaceutical products reaching the end of their patent lives, a whole new market field — biogenerics, or biosimilars — is opening up, for those generics companies capable of (or prepared to buy in) the technological expertise required.
- The international landscape is changing for generics as for all pharmaceuticals. The BRIC nations (Brazil, Russia, India and China) are among rising centers of generic activity.
SCOPE OF REPORT
This report discusses the implications of all the above-mentioned trends, in the context of the current size and growth of the generics market, both in global terms and analyzed by the most important national markets. The nature and structure of the generics industry is discussed, with profiles of the leading 20+ generics companies and an update on M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.
MARKET ANALYSES AND FORECASTS
Market figures are based on revenues at the manufacturer level and are projected on the basis of 2016 dollar value without attempting to predict the effect of inflation/deflation.
Therapeutic categories quantified and forecast include antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g. hypolipidemics and antihypertensive) and drugs for respiratory conditions, including asthma and COPD.
Primary research includes interviews with leading individuals in generics companies, industry associations and regulatory bodies. Primary sources of published data include company annual reports, SEC filings, and government and industry publications. Secondary sources consist of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources, critically assessed by BCC Research.
This report is designed to satisfy the information needs of a wide variety of individuals involved in the generics marketplace, including corporate senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. It is also aimed at managers and executives in marketing, research, planning and sales departments who need readable, comprehensive and up-to-date background on the marketplace in which they are operating.
Sources of information included marketing strategists, industry executives, government agencies and regulatory bodies, and surveys of physicians and pharmacists. Company annual reports and SEC filings, journal articles and data from healthcare institutions were also mined, as well as publications of trade associations such as the Generic Pharmaceutical Association (GPhA) and the European Generic Medicines Association (EGA).
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of three previous reports on the generics marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762